Immuron (FRA:ANW) Short-Term Capital Lease Obligation : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Immuron Short-Term Capital Lease Obligation?

Immuron's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil.

Immuron's quarterly Short-Term Capital Lease Obligation increased from Dec. 2022 (€0.02 Mil) to Jun. 2023 (€0.02 Mil) but then declined from Jun. 2023 (€0.02 Mil) to Dec. 2023 (€0.00 Mil).

Immuron's annual Short-Term Capital Lease Obligation increased from Jun. 2021 (€0.01 Mil) to Jun. 2022 (€0.02 Mil) and increased from Jun. 2022 (€0.02 Mil) to Jun. 2023 (€0.02 Mil).

Immuron Short-Term Capital Lease Obligation Historical Data

The historical data trend for Immuron's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Short-Term Capital Lease Obligation Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.03

0.01

0.02

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial												0.02	0.02	0.02	0.02	-

Immuron Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Immuron Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Immuron's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (FRA:ANW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines